[PDF] Top 20 Primary IgA nephropathy: current challenges and future prospects

... Recent research has generated greater insight into poten- tial therapeutic targets for IgAN. Deeper understanding of the roles of the mucosal immune barrier, complement activa- tion and deposition, and T-cell dependent ... See full document

... the current available literature on screening for risk factors for PTB and a summary of preventive strategies in both low-risk and high-risk women with singleton or multiple ...Furthermore, current ... See full document

... Abstract: Neurocysticercosis (NCC) is an acquired infection of the nervous system caused by encysted larvae of Taenia solium. It is a major cause of epilepsy in the tropics and the commonest cause of focal seizures in ... See full document

... the current challenges and the future prospects in relation to the diagnosis and treatment of AIH, which have been attracting considerable recent ... See full document

... transplant recipients, now older children, adolescents, and young adults, return with medically resistant chronic graft dysfunction. This represents a particularly difficult population to manage. Some require relisting ... See full document

... main challenges and opportuni- ties in the way of promoting deliberative democracy or SDM in the health care systems as identified in previous reviews and other theoretical and empirical ... See full document

... Through IGLEs and IMAs a bolus transmits sensory information to the solitary nucleus via the nodose ganglion to regulate the intensity and timing of vagal output via vagal dorsal mot[r] ... See full document

... The primary efficacy end point was mean change in serum potassium level from base- line to week 4, which was significantly reduced with every dose of Patiromer from ... See full document

... The frequency of exposure to chlorhexidine by at least one route is very high. Therefore, the possibility of accidental exposure remains challenging for these patients. The lack of standardized and clear chlorhexidine ... See full document

... The literature indicates that approximately two-thirds of patients with depression do not achieve remission to an initial treatment and that the likelihood of nonresponse increases with the number of treatments trialed. ... See full document

... important. Future prospects for improved care include the coordinated implementation and monitoring of services, collaborative care models integrating management of comorbid mental health, better strategies ... See full document

... Abstract: Cold agglutinin disease (CAD) is a complement-dependent, classical pathway- mediated immune hemolytic disease, accounting for 15 – 25% of autoimmune hemolytic anemia, and at the same time, a distinct clonal ... See full document

... Incongruous and various types of responses have been observed in the MS patients receiving the DMTs. These patients need to be implemented with predictive exam- inations under the personalized medicine concepts to ori- ... See full document

... the data came from retrospective case series, and over half of published papers were case reports. Though compiling doz- ens of case reports may be instructive, without randomized controlled trials, this research is ... See full document

... In the case of response (return of sCr to a value within 0.3 mg/dl of the baseline), patients should be followed closely for early identi fi cation of eventual recurrences. 29 Alternatively, in the case of non-response, ... See full document

... Abstract: Understanding of molecular mechanisms of tumor growth has an increasing impact on the development of diagnostics and targeted therapy of human neoplasia. In this review, we summarize the current ... See full document

... In the group treated with the device designed for home-based photo- therapy, only eight out of 20 patients had complete clearance of their psoriatic lesions, compared to 18 out [r] ... See full document

... compared to placebo for mCRC patients who had received all prior chemotherapy plus anti-VEGF therapy and/or anti- EGFR mAB for RAS WT mCRC. 9 The primary endpoint was met, with median OS 7.1 versus (v) 5.3 months ... See full document

... Another Japanese trial investigated efficacy and safety of trametinib in Japanese patients with advanced BTC refrac- tory to GEM-based therapy. In this Phase IIa open-label, single-arm trial, patients received oral ... See full document

... whether pyloroplasty alone will suffice, or a combination of GES implantation and pyloroplasty will lead to better clini- cal outcomes. A double-blind study is under current clinical investigation to address this ... See full document